| abstract |
The present invention provides a rapid action with respect to a decrease in gastric acid secretion in the resting phase, an increase in gastric pH and a decrease in the period of gastric acid release in the secretion promoting period, and optionally provides a long-term effect, and the stomach To treat conditions such as esophageal reflux disease (GERD), non-erosive gastroesophageal reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease and gastric cancer, and to prevent or reduce the risk of ulcer disease To provide therapeutic agents. The use of a pharmaceutically acceptable zinc salt, preferably a water soluble zinc salt alone, or optionally a proton pump inhibitor (PPI), H2 blocker, anti-H. Use in combination with one or more of the following agents: H. pylori antibiotic / antibacterial agent, cytoprotective agent. Useful for treating patients who do not respond to proton pump inhibitors (PPI) or for treating conditions caused by rapid and complete inhibition of secretagogues that induce acid secretion . [Selection figure] None |